Previsioni

Acquista	1
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Satellos appoints Antoinette Paone as chief development officer

Satellos appoints Antoinette Paone as chief development officer and head of regulatory affairs to advance development of its therapies for muscle diseases. Paone joins from Generation Bio, where she was most recently chief operating officer, and brings experience from a ten-year tenure at Vertex, where she led approval programs for cystic fibrosis therapies. Satellos is pursuing the orally administered agent SAT-3247 as a treatment for Duchenne muscular dystrophy; ongoing clinical trials in adults and children are intended to bring it closer to potential approval. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Satellos Bioscience ha registrato ricavi pari a 0 € e un utile netto di -6,22 Mln €

(EUR)	dic 2025	YoY
Ricavi	0	-
Utile lordo	0	-
Utile netto	-6,22 Mln	-
EBITDA	-6,52 Mln	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	83,38 Mln €
Numero di azioni	15,46 Mln
Massimo/minimo a 52 settimane	10,79 € - 0,76 €
Dividendi	No
Beta	0,71
Rapporto P/E	-1,75
Rapporto PEG	-0,01
Rapporto P/B	0,49
Rapporto P/S	0,00

Profilo aziendale

Satellos Bioscience Inc. ist ein Unternehmen für regenerative Medizin und entwickelt Therapeutika zur Behandlung degenerativer Muskelkrankheiten. Das Hauptprogramm des Unternehmens konzentriert sich auf die Entwicklung eines oralen therapeutischen Medikaments zur Korrektur der Polarität von Muskelstammzellen und zur Wiederherstellung des körpereigenen Muskelreparatur- und Regenerationsprozesses. Das Unternehmen wurde 2012 gegründet und hat seinen Hauptsitz in Toronto, Kanada.